Genmab — Maj 2019

[E_L]

the 2 oral presentations, COLUMBA http://abstracts.asco.org/239/AbstView_239_265165.html and CASSIOPEIA http://abstracts.asco.org/239/AbstView_239_259347.html

[Sukkeralf]

Isatuximab: http://abstracts.asco.org/239/AbstView_239_257917.html

[E_L]

the sooner SC approved the better, to keep Isa behind...

[Sukkeralf]

Enapotamab: http://abstracts.asco.org/239/AbstView_239_250307.html

[Sukkeralf]

Yes isa data looks like dara data (quick view)

[Sukkeralf]

Not that many responses with out AXL ADC - but hopefully to early to get a real feeling

[Sukkeralf]

with our

[E_L]

it says " EnaV had encouraging preliminary anti-tumor activity and will be evaluated in 7 ph2a expansion cohorts" ; all the other stuff is on safety, if I read it correctly?

[Sukkeralf]

3 pts (1Q3W arm) had partial response (1 NSCLC [2.2 mg/kg dose]; 2 ovarian [1.5 and 2.4 mg/kg dose levels]).

[E_L]

ok, thks, that is out of n=15 then for that arm

[Solsen]

Venclexta fik approval i går. De indsendte 5 dage før MAIA også under RTOR. Så vi er sikkert tæt på afgørelsen. Kilde Handelsbanken

[Sukkeralf]

n=15 ? n=32 right ?

[E_L]

yes, 2nd correction (1Q3W n=32; 3Q4W n=15).
Time for another coffee

[E_L]

then indeed not that many responses as you say, safety profile seems very manageable so far though in that dosing
?

[Bulder]

Columba looks fine: significantly lower rate of IRRs. Median(!) duration of injection was 5 mins.

[Bulder]

SC=home run

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[nohope]

3xpartial response - does it have any value at all then ?

[Solsen]

Nordea regner med 8-12% royalty på JNJ duobodies. De overhørte JNJs session i går og ser dara sc i solide opstartet i 2020.

[JohnW]

dara sc i solide?